Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-18-000074

Chief Legal Officer sold 31,000 shares at an average $22.72 ($704,280)

  • Chief Legal Officer acquired 16,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Dylan-Hyde Tyler · Chief Legal Officer

Table I: Non-derivative

8 lines
Date Transaction Shares Price Value Owned after D/I
2017-12-28 Exercise or conversion : show line 1 in the form +700 $14.43 $10,101 115,904 D
2017-12-28 Sale : show line 2 in the form −700 $21.75 $15,225 115,204 D
2017-12-29 Exercise or conversion : show line 3 in the form +6,230 $14.43 $89,899 121,434 D
2017-12-29 Sale : show line 4 in the form −6,230 $21.75 $135,503 115,204 D
2017-12-29 Exercise or conversion : show line 5 in the form +9,070 $12.57 $114,010 124,274 D
2017-12-29 Sale : show line 6 in the form −1,070 $21.75 $23,273 123,204 D
2017-12-29 Sale : show line 7 in the form −8,000 $23.76 $190,080 115,204 D
2017-12-29 Sale : show line 8 in the form −15,000 $22.68 $340,200 100,204 D
Open-market sales · 31,000 sh · avg $22.72 · $704,280

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2017-12-28 Exercise or conversion : show line 9 in the form Stock Option (Right to Buy) −700 64,300 D
2017-12-29 Exercise or conversion : show line 10 in the form Stock Option (Right to Buy) −6,230 58,070 D
2017-12-29 Exercise or conversion : show line 11 in the form Stock Option (Right to Buy) −9,070 44,263 D
Loading xslF345X03/doc4.xml…